Table 2

Rates of all severe infections, according to agent, number of courses, and main autoimmune diseases

Patients

Person-years

Number of infections

Rate of infections/

1,000 person-years

95% Confidence interval


TOTAL

344

495

45

90.90

66.31 to 121.64

RITUXIMAB

- Total

264

328.83

37

112.52

79.20 to 155.10

- First course

211

252.17

30

119.00

88.03 to 169.80

- Second course

38

54.58

2

36.64

4.44 to 132.37

- Third or subsequent courses

15

22.08

5

226.40

73.50 to 528.50

ANTI-TNF AGENTS

- Total

77

147.58

8

54.21

23.40 to 106.81

- Infliximab

37

52.00

4

76.92

20.96 to 196.95

- Adalimumab

19

29.91

2

66.85

8.10 to 241.55

- Etanercept

21

65.67

2

30.46

3.69 to 110.02

DISEASES

- SLE

140

175.42

11

62.71

31.30 to 112.20

- Systemic vasculitis

50

74.75

11

147.16

73.50 to 263.30

- Inflammatory myopathies

38

60.42

7

115.86

46.60 to 238.70

- Behçet disease

31

61.25

2

32.65

3.95 to 117.95

- Sjögren syndrome

23

31.92

3

93.98

19.38 to 274.66

DISEASE/AGENT

- Behçet disease/IFX

20

36.50

1

27.39

0.68 to 152.65

- Cryoglobulinemia/RTX

15

14.17

4

282.30

76.90 to 722.80

- Wegener granulomatosis/RTX

18

29.00

4

137.90

37.60 to 353.20

- SLE/RTX

139

171.08

11

64.30

32.09 to 115.04

- Inflammatory myopathies/RTX

27

32.17

2

62.18

7.53 to 224.61

- Sjögren syndrome/RTX

21

24.00

3

125.00

25.80 to 365.30

INDICATION

- Refractory disease

296

421.17

38

90.22

63.85 to 123.84

- Life-threatening situation

48

73.83

7

94.81

38.12 to 195.35


IFX, infliximab; RTX, rituximab; SLE, systemic lupus erythematosus.

Díaz-Lagares et al. Arthritis Research & Therapy 2011 13:R112   doi:10.1186/ar3397

Open Data